FDA staffing
This article was originally published in The Tan Sheet
Executive Summary
Sandra Kweder, MD, named ODE II acting director effective Jan. 13, filling post vacated by John Jenkins, MD, who is now Office of New Drugs director. Jenkins, Kweder essentially swapped roles, as Kweder was former acting director of Office of Review Management, now known as OND (1"The Tan Sheet" Dec. 17, 2001, p. 9)...
You may also be interested in...
FDA Drug Review Head Is Jenkins, Ending 15-Month Search
Office of Drug Evaluation II Director John Jenkins, MD, will take over as FDA's top drug review manager effective Jan. 2. The agency announced the appointment of Jenkins as Office of Review Management director in a staff memo Dec. 11
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.